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optical density (OD). The optical density distributions were then 
corrected for the acquisition-related distortion by means of an 
algorithm available in literature. The dose fluctuation pattern 
inherent to helical TomoTherapy was then extracted by applying 
another band-pass filter. Finally, after the application of an OD-dose 
calibration, the dose distributions were filtered in order to reduce low 
and high frequency noise. For the selection of the most suitable filter 
various possibilities were tested, including the complete removal of 
the predetermined frequency range which characterizes the batch. 
The quality of the uniformity correction protocol was evaluated by 
comparing passing rates obtained with films and those achieved with 
PTW OCTAVIUS system. 
Results: The level of dose sensitivity variations depends on the 
specific batch [2-4] %. The frequency range seems to be similar for 
intra-batch films, while different for inter-batch films. The pure 
elimination of the band frequency range is not applicable. This is 
because the frequencies that characterized the dose sensitivity 
variations and those that characterized the dosimetric information are 
comparable. The best low and high frequency noise reduction is 
obtained by applying the wavelet filtering method and separately 
adding the dose fluctuation pattern inherent to helical TomoTherapy 
to the SBRT dose distribution. Using a gamma function 3mm-3%, 
agreement between planned and measured dose distributions was 
found to be always better then 90% only if the correction protocol was 
applied. 
  
Conclusions: Radio chromicfilms response, if corrected by our 
protocol, can be used for the verification of TomoTherapy SBRT plans 
where high spatial resolution is needed.  
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Purpose/Objective: QA phantoms for dose verification of complex 
radiation treatments such as IMRT and VMAT are currently in 
widespread use. By monitoring beam or control point dose in a large 
number of small detectors distributed within the QA phantom and 
comparing measured dose with TPS calculated dose in the QA 
phantom, accurate confirmation of spatial deviations between 
planned and delivered dose can be obtained.The clinical 
interpretation of deviations is however limited by the fact that doses 
are being compared in the QA phantom. To facilitate evaluation of the 
clinical impact of observed dose deviations, the TPS calculated dose 
in the patient should ideally be compared with the patient dose 
distribution corresponding to the measured doses in the QA phantom. 
Materials and Methods: This work describes the development and 
validation of a novel technique for accurate and reliable 3D photon 
dose calculation in a patient volume based on detector dose 
measurements in a QA phantom of arbitrary material. The technique 
consists of two steps: 
1. For the given beam quality and accounting for the phantom 
composition, estimate the 2D energy fluence distribution that best 
represents the measured detector doses in the QA phantom. 
2. Apply the obtained energy fluence and the given beam quality in a 
3D dose calculation for the patient volume. 
The estiated energy fluence distribution represents the radiant energy 
resulting from modulation and collimation in the treatment 
head,independent of dose calculation geometry. Presence or absence 
of flattening filter is automatically accounted for. 
The energy fluence estimation is formulated as a linear optimization 
problem, where the objective is to minimize the integral fluence 
given that the calculated phantom dose in every accountable detector 
position is greater than or equal to the measured dose. This 
formulation is guaranteed to have a feasible solution and the 
calculated-to-measured dose deviation is implicitly minimized through 
the integral fluence objective. 
Results: The technique has been applied to both MLC collimated IMRT 
fields with non-uniform energy fluence and VMAT fields where patient 
dose is calculated for the individual control points and subsequently 
added to yield a total 3D dose. The technique is consistently able to 
reproduce reference absolute dose results within 3% and 3 or 6 mm, 
depending on the local spatial resolution of the detector grid. 
Conclusions: A technique for calculating 3D photon dose in the 
patient volume based on measured detector doses in a QA phantom 
has been implemented. The technique is applicable to complex 
treatments such as IMRT and VMAT and has been shown to accurately 
and reliably obtain 3D patient dose distributions that can be 
immediately compared with 3D dose distributions planned and 
calculated with a regular treatment planning system. 
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Purpose/Objective: Treatment planning system (TPS) capabilities 
should beverified in a real 3D situation with rigorous procedures, both 
for static and rotational modulated fields. 
The American Association of Physicists in Medicine TaskGroup 119 
(TG119) proposed a water equivalent square slab phantom (30x30x15 
cm3) with four IMRT tests: mock prostate (MP), head-and-neck (HN), 
C-shaped target (CS), and Multi Target (MT). Each test was developed 
to assess the overall accuracy of planning and delivery of IMRT 
treatments. The test suite with DICOM-RT images and structures can 
be downloaded from the AAPM web-site. TG119 defines also beams 
arrangement, IMRT goals, and methods for analyzing the dosimetric 
results on their phantom. The AAPM phantom is cheap and easily 
reproducible in every department, but it allows only single point or 
single planar measurements. In order to apply the TG119 report in a 
more sophisticated situation we used a 3D dosimetric phantom and all 
tests were re-optimized to satisfy all defined goals. 
Materials and Methods: TG119 was pre-emptively used 'as is' in order 
to test the capability of our clinical arrangement. After this, TG119 
structures were superimposed on the CT images of a cylindrical PMMA 
phantom surrounding two orthogonal matrix with 1069 total diodes 
(Delta4 - 3D dosephantom; Scandidos, SWE). TG119 tests were thus 
calculated and optimized using a Monte Carlo TPS (Monaco3.20; 
Elekta, SWE) for 6 and 10 MV photon beams, with IMRT and VMAT 
techniques, following the plan proposed goals. Delta4 phantom was 
used in order to carryout comparison between measured and planned 
3D absolute dose distributions. A 3%, 3mm with a 10% threshold 
(defined by the isodose line representing 10% of maximum dose) 
gamma test was performed for plans analysis.  
Results: Goals proposed in TG119 were satisfied for each planand 
technique. For all IMRT plans gamma values were lower than 1 for 
more than 98.3% of compared point, except for the CS plan delivered 
with 6 MV (Fig.1), where gamma analysis was satisfied for 90.5% of 
total points. The mean percentage of passing points for all energies 
was 98.4 ± 3.3%. Preliminary results were obtained for VMAT cases, 
with a mean percentage of 88.5 ± 8.4%. VMAT is at present under 
refinement and better results are expected after the optimisation of 
the Monte Carlo model. 
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Conclusions: TG119 structures and plans were found to be easily 
adaptable to Delta4 phantom CT enabling a rigorous evaluation 
procedure for IMRT plans verification. Preliminary results on VMAT 
plans showed that TG119 could be a practical commissioning 
procedure for modulated arc therapy too. Delta4 allows a fast on-line 
3D dose distributions analysis substituting more traditional dosimeters 
suggested in TG119, but this solution is more expensive than the one 
proposed inside this report and it is not available in every department 
for intercomparison purposes. 
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Purpose/Objective: Quality control (QC) of volumetric modulated arc 
therapy (VMAT) delivery represents a significant additional workload 
during monthly accelerator checks. This study therefore aims to 
implement VMAT QC in as few arcs as possible using portal imaging. 
Synchronisation between gantry position, multileaf collimator (MLC) 
leaves and dose rate is the focus of the study, since this is the aspect 
which is covered least by already-implemented tests of intensity 
modulated radiation therapy (IMRT) delivery. 
Materials and Methods: An Agility accelerator with iViewGT portal 
imager (Elekta AB, Stockholm, Sweden) was used for this study. A 
steel bar of diameter 12 mm was accurately positioned in the G-T 
direction, 80 mm laterally from the isocentre (Figure 1a). An arc 
prescription was designed which irradiated the bar with a 16 mm x 
220 mm field during a complete 360° arc, so as to cast a shadow of 
the bar onto the portal imager. This resulted in a sinusoidal sweep of 
the field and shadow across the portal imager and back. The 
prescribed monitor units (MU) were chosen so as to give a uniform 
intensity during this sweep. A total of 640 MU were delivered with 
control point spacing 10°. The method was tested by simulating an 
MLC leaf position error of 2 mm at one control point, a gantry position 
error of 9° at one control point, and a dose error of 20 MU (3% of 
overall dose) at one control point. The portal images were viewed as 
integrated images. Coefficient of variation of mid-leaf profiles was 
used to evaluate the magnitude of features appearing in the portal 
images due to simulated errors. 
Results: The test requires a counter-clockwise arc and a clockwise arc 
to fully evaluate the VMAT performance of all MLC leaves. In the 
absence of simulated errors, the integrated images show uniformity. 
With simulated delivery errors, irregular patterns appear in the 
integrated portal images (Figures 1b - 1d). The increase in coefficient 
of variation relative to no delivery error is 42% due to a 2 mm MLC 
leaf position error at one control point, 108% due to a 9° gantry 
position error at one control point and 239% due to a 20 MU dose error 
at one control point. The method is more sensitive to errors at gantry 
angle 90°/270° than at 0°/180° due to the geometry of the test. 
Conclusions: This method provides fast and effective VMAT QC 
suitable for inclusion in a monthly accelerator QC programme. The 
test is able to detect errors in the delivery of individual control 
points, with the possibility of using movie images to further 
investigate suspicious image features. We are grateful for engineering 
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Purpose/Objective: The predictive role of FDG-PET in identifying lung 
cancer patients at risk of relapse has opened for PET-guided 
simultaneous integrated boost (SIB), where the PET-active tumor 
region may be dose escalated [1]. Such treatment involves intensity 
modulated radiotherapy (IMRT), with a high degree of beam 
modulation, of a target positioned in the lungs. Dose calculation 
algorithms may show deficiencies under such conditions, and it is thus 
pivotal to verify whether the planned dose is correctly delivered. 
Materials and Methods: An anthropomorphic thorax phantom made of 
polystyrene (ρ=1.06,soft tissue surrogate) and polyurethane 
(ρ=0.25,lung tissue surrogate) was constructed in-house based on CT 
images of a lung cancer patient. One-hundred and one cylindrical 
cavities for alanine/EPRdosimeters (height 2.5 mm, diameter 5 mm) 
were made throughout the phantom. A SIB based on PET/CT images of 
the given patient was planned for a Varian Trilogy linear accelerator 
equipped with a 120 leaf Millennium multileaf collimator (Varian 
Medical Systems) using 6 MV photons. The IMRT boost plan objectives 
comprised, among others, a boost dose of 3.8 Gy/fraction to the FDG-
avid region including margins (biological planning volume; BTV) with 
3.1 Gy/fraction to the planning target volume (PTV, excluding the 
BTV). The IMRT plan was transferred to the anthropomorphic phantom 
where the dose distribution was calculated using the AAA algorithm in 
the Eclipse treatment planning system. Irradiation of the phantom, 
including 101 alanine/EPR dosimeters, was carried out at the linear 
accelerator in question. Phantom setup was verified with the 
accompanying OBI cone beam CT system, and portal dosimetry was 
performed for beam verification. A dosimeter calibration series with 
15 dosimeters was irradiated at the same accelerator. Readout of the 
alanine/EPR dosimeters were performed at an EleXsyS 560 Super X 
EPR spectrometer. 
Results: The phantom dose points were separated into four region 
categories; BTV, PTV (excluding BTV),lung tissue and nonspecific soft 
tissue. The mean measured versus calculated point doses within these 
regions were 3.83 vs3.84 Gy, 3.30 vs 3.29 Gy, 1.68 vs 1.63 Gy and 0.36 
vs 0.33 Gy, respectively. The mean relative difference in point doses 
(± 1 S.D.) between measurement and plan were (-0.5±1.8) %, 
(0.4±2.9) %,(5±13) % and (14±36) %, respectively. A high linear 
correlation between measured and planned doses (range 0.71-0.99) 
was seen in all regions. 
Conclusions: The PET-guided SIB can be delivered to patients with 
high dosimetric accuracy with the given planning and delivery system. 
Although some discrepancies are observed between measurements 
and calculations, these are mostly seen in non-specific soft tissue 
receiving very low doses and are most likely not clinically relevant. 
[1] van Elmpt, W., De Ruysscher, D., van der Salma,A., et al. The PET-
boost randomised phase II dose-escalation trial in non-small cell lung 
cancer. Radiother Oncol 2012; 104: 67-71. 
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Purpose/Objective: The aim of this work was to extend an EPID-based 
in-vivo dosimetry (IVD) method, developed in the last years by the 
authors for conformal radiotherapy, to step-and-shoot IMRT 
treatments of pelvic tumours. The algorithm was developed for Elekta 
linacs equipped with IviewGT EPIDs, with the aim to simplify the 
commissiong procedures and supply IVD tests in quasi-real time. 
Materials and Methods: The algorithm is based on correlation 
functions to convert EPID transit signals into in-vivo dose values, Diso, 
at the isocenter point. The EPID images were obtained by the so-
called 'IMRT Dosimetric Weighting' mode as a superposition of many 
segment fields. Each integral dosimetric image could be acquired in 
about 10 s after the end of beam delivery and could be processed 
while delivering the successive IMRT beams. A specific algorithm for 
